« Back
Dicerna™ Appoints Rob Ciappenelli Chief Commercial Officer
Jun 04, 2019
— Company Expands Management Team and Bolsters Commercial Capabilities to Support Continued Growth —
“Rob is a proven global business executive with deep and diverse
experience leading commercial operations in our industry,” said
With more than 28 years of global experience across the pharmaceutical,
biotech and healthcare consulting industries, Mr. Ciappenelli brings to
Dicerna extensive experience in developing commercial organizations and
establishing lean operational infrastructure. Through leadership roles
with
“I am drawn to Dicerna by its people, its pipeline of next-generation RNAi therapies and the transformative potential of its GalXC technology platform,” said Mr. Ciappenelli. “I am eager to work with the talented team at Dicerna to build and implement the Company’s commercial strategy and fulfill its mission of improving the lives of patients with serious, life-threatening diseases.”
Mr. Ciappenelli joins Dicerna from
Mr. Ciappenelli earned a Bachelor of Business Administration (B.B.A.) in
Finance from the
About Dicerna™
Dicerna™
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include risks relating to Dicerna’s clinical and preclinical research and other risks identified under the heading "Risk Factors" included in the Company’s most recent Form 10-Q filing and in other future filings with the SEC. The forward-looking statements contained in this press release reflect Dicerna's current views with respect to future events, and Dicerna does not undertake and specifically disclaims any obligation to update any forward-looking statements.
Dicerna™, GalXC™ and PHYOX™ are trademarks of
View source version on businesswire.com: https://www.businesswire.com/news/home/20190604005332/en/
Source: Dicerna™
Investors:
Stern Investor Relations, Inc.
Kendra Packard,
212-362-1200
Kendra.packard@sternir.com
Media:
SmithSolve
Alex Van Rees, 973-442-1555 ext. 111
alex.vanrees@smithsolve.com